ES2855577T3 - Molécula de ácido nucleico funcional y uso de la misma - Google Patents

Molécula de ácido nucleico funcional y uso de la misma Download PDF

Info

Publication number
ES2855577T3
ES2855577T3 ES12763652T ES12763652T ES2855577T3 ES 2855577 T3 ES2855577 T3 ES 2855577T3 ES 12763652 T ES12763652 T ES 12763652T ES 12763652 T ES12763652 T ES 12763652T ES 2855577 T3 ES2855577 T3 ES 2855577T3
Authority
ES
Spain
Prior art keywords
sequence
rna
protein
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12763652T
Other languages
English (en)
Spanish (es)
Inventor
Piero Carninci
Alistair Forrest
Stefano Gustincich
Claudia Carrieri
Silvia Zucchelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Int School For Advanced Studies
Harness Therapeutics Ltd
International School For Advanced Studies
Original Assignee
Int School For Advanced Studies
Transine Therapeutics Ltd
International School For Advanced Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int School For Advanced Studies, Transine Therapeutics Ltd, International School For Advanced Studies filed Critical Int School For Advanced Studies
Application granted granted Critical
Publication of ES2855577T3 publication Critical patent/ES2855577T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
ES12763652T 2011-03-30 2012-03-30 Molécula de ácido nucleico funcional y uso de la misma Active ES2855577T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469399P 2011-03-30 2011-03-30
PCT/JP2012/059430 WO2012133947A1 (en) 2011-03-30 2012-03-30 Functional nucleic acid molecule and use thereof

Publications (1)

Publication Number Publication Date
ES2855577T3 true ES2855577T3 (es) 2021-09-23

Family

ID=46931619

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12763652T Active ES2855577T3 (es) 2011-03-30 2012-03-30 Molécula de ácido nucleico funcional y uso de la misma

Country Status (5)

Country Link
US (1) US9353370B2 (enExample)
EP (2) EP2691522B1 (enExample)
JP (3) JP2014514921A (enExample)
ES (1) ES2855577T3 (enExample)
WO (1) WO2012133947A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105624156B (zh) * 2014-11-04 2021-07-16 清华大学 含有反向sineb2重复序列的人工非编码rna及其在增强靶蛋白翻译中的用途
IT201700105372A1 (it) * 2017-09-20 2019-03-20 Fondazione St Italiano Tecnologia Molecola di acido nucleico funzionale e relativo uso
IT201800002411A1 (it) * 2018-02-05 2019-08-05 Scuola Int Superiore Di Studi Avanzati Sissa Domini strutturali di molecole di rna antisenso che aumentano la traduzione
IT201900011490A1 (it) * 2019-07-11 2021-01-11 Scuola Int Superiore Di Studi Avanzati Sissa MOLECOLE DI ACIDO NUCLEICO FUNZIONALI CHE AUMENTANO LA TRADUZIONE DI UN mRNA DELLA FRATASSINA
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
CN116322791A (zh) * 2020-09-24 2023-06-23 意大利技术基金会 经修饰的功能性核酸分子
KR20230131175A (ko) 2020-10-08 2023-09-12 트랜사인 테라퓨틱스 리미티드 기능성 핵산 분자
EP3992289A1 (en) 2020-10-30 2022-05-04 Transine Therapeutics Limited Functional nucleic acid molecules incorporating protein binding domain
US20240088484A1 (en) 2021-01-18 2024-03-14 Ibiden Co., Ltd. Heat transfer suppression sheet for battery pack, and battery pack
EP4063505A1 (en) 2021-03-22 2022-09-28 Fondazione Istituto Italiano di Tecnologia Functional nucleic acid molecules directed to targets for nervous system disorders
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
GB202205423D0 (en) 2022-04-12 2022-05-25 Transine Therapeutics Ltd Functional nucleic acid molecule
GB202207796D0 (en) 2022-05-26 2022-07-13 Fondazione St Italiano Tecnologia Functional nucleic acid molecule
GB202207795D0 (en) 2022-05-26 2022-07-13 Fondazione St Italiano Tecnologia Functional nucleic acid molecule
IT202200011546A1 (it) 2022-06-01 2022-09-01 Univ Degli Studi Di Trento Sequenze di RNA non codificanti in grado di aumentare l'espressione delle proteine CHD8 e CHD2
WO2025133858A1 (en) 2023-12-18 2025-06-26 Fondazione Istituto Italiano Di Tecnologia Functional nucleic acid molecule capable of increasing bdnf production

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
CA2857878A1 (en) * 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
WO2008113773A2 (en) 2007-03-16 2008-09-25 Biorigen S.R.L. Gene expression regulation technology and noncoding rnas for diagnosis and therapy
US8367320B2 (en) * 2007-12-28 2013-02-05 Qiagen Sciences, Inc. Apoptosis inducing positive control for expression modulation experiments
JP2010273680A (ja) 2009-05-29 2010-12-09 Kyoto Univ 初期化因子が除去された人工多能性幹細胞の作製方法
JP5696282B2 (ja) 2009-06-10 2015-04-08 国立大学法人京都大学 人工多能性幹細胞樹立効率改善剤
JP2011004674A (ja) 2009-06-26 2011-01-13 Fujitsu Ltd 誘導多能性幹細胞（ｉＰＳ細胞）の製造方法
US8709805B2 (en) 2009-08-07 2014-04-29 Kyoto University Canine iPS cells and method of producing same

Also Published As

Publication number Publication date
EP3792359A1 (en) 2021-03-17
EP2691522A1 (en) 2014-02-05
EP2691522A4 (en) 2014-11-05
US9353370B2 (en) 2016-05-31
EP2691522B1 (en) 2020-11-25
JP2021006047A (ja) 2021-01-21
JP2017169573A (ja) 2017-09-28
US20140107187A1 (en) 2014-04-17
WO2012133947A1 (en) 2012-10-04
JP6770921B2 (ja) 2020-10-21
JP7229487B2 (ja) 2023-02-28
JP2014514921A (ja) 2014-06-26

Similar Documents

Publication Publication Date Title
JP7229487B2 (ja) 機能性ｒｎａ分子、及びその利用
Alexander et al. MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation
Liu et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice
Huang et al. Regulation of nonsense‐mediated mRNA decay
Bon et al. SINEUP non-coding RNAs rescue defective frataxin expression and activity in a cellular model of Friedreich's Ataxia
ES2659845B1 (es) Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
Lu et al. lncRNA‐CIR regulates cell apoptosis of chondrocytes in osteoarthritis
Church et al. Microprocessor recruitment to elongating RNA polymerase II is required for differential expression of microRNAs
Overby et al. Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
WO2016113544A1 (en) Treatment of diseases associated with mitochondrial dysfunction
Ma et al. An androgen receptor-microrna-29a regulatory circuitry in mouse epididymis
Hosokawa et al. Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes
Meseguer et al. mt tRFs, new players in MELAS disease
JP2010184879A (ja) 抗筋萎縮剤
JP2023545083A (ja) 機能性核酸分子
Reyes-Juarez et al. Transcriptional analysis of the human cardiac calsequestrin gene in cardiac and skeletal myocytes
Xu et al. cAMP-mediated stimulation of tyrosine hydroxylase mRNA translation is mediated by polypyrimidine-rich sequences within its 3′-untranslated region and poly (C)-binding protein 2
JP7776924B2 (ja) 変異ＦＵＳの発現を選択的に抑制する修飾ｓｉＲＮＡ
Zheng et al. Autoantigen La regulates microRNA processing from stem–loop precursors by association with DGCR8
Rybarikova et al. Gene editing for Spinocerebellar ataxia type 3 taking advantage of the human ATXN3L paralog as replacement gene
Pierattini SINEUP lncRNAs: from molecular mechanism to therapeutic application.
CN115873935B (zh) Hilnc或包含其的信号通路作为调控脂质代谢的靶标的应用
WO2020002691A1 (en) TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
Niimi et al. Involvement of an alternatively spliced mitochondrial oxodicarboxylate carrier in adipogenesis in 3T3-L1 cells
Sirey et al. Cerox1 and microRNA-488-3p noncoding RNAs jointly regulate mitochondrial complex I catalytic activity